We are proud to announce that Rarity Bioscience is partnering with Beckman Coulter Life Sciences – a collaboration that will elevate oncology research by making the superRCA technology accessible to a global audience.
Expanding Flow Cytometry's Capabilities
Partnering with Beckman Coulter Life Sciences enables the global distribution of Rarity Bioscience’s ultra-sensitive superRCA assays, ensuring broader access to meet the growing demand for enhanced mutation detection sensitivity. Requiring a flow cytometer for read-out, the assay is easily accessible to laboratories without the need for specialized equipment.
The collaboration not only extends the capabilities of flow cytometry in molecular research but also supports advancements in oncology research and molecular detection by expanding the global reach of the superRCA assay.
“It is with great excitement we are entering into this partnership. Our strategic decision to develop superRCA technology for use with widely adopted flow cytometry platforms was driven by the goal of enabling rapid scalability and providing laboratories and researchers with immediate access to high-precision molecular testing. Partnering with Beckman Coulter Life Sciences, a global leader in flow cytometry, further reinforces this strategy and allows us to focus on expanding our platform’s capabilities within MRD assays and beyond.”
Beckman Coulter Life Sciences
Beckman Coulter Life Sciences is a global leader in clinical diagnostics, with more than 90 years of experience in elevating the laboratory’s role in improving patient health. Their diagnostic solutions are used in hospitals, reference and research laboratories, and physician offices around the world. Read more on their website: www.beckman.com
Read more about the partnership here:
